One Drug. Three fatal diseases. Zero current cures.
ENIGMA Bio is developing a single RNAi therapeutic that addresses three fatal diseases with no current cures. Our platform unlocks a new class of treatments by silencing the genetic drivers of disease at the source.
We've built proprietary delivery and targeting technology, filed patents, and are currently in discussions with select investors under NDA. Full pipeline, preclinical data, and financial details are available to qualified partners.
We share our technology, pipeline, and preclinical data with qualified investors under NDA. Reach out to start the conversation.